Table 2 |
|||
|
Demographic data and baseline characteristics (randomised set) |
|||
|
Total |
Intradermal vaccine |
Adjuvanted vaccine |
|
|
N = 795 |
N = 398 |
N = 397 |
|
|
|
|||
|
Mean age (years; SD) |
74.3 (6.4) |
73.9 (6.3) |
74.7 (6.6) |
|
- over 75 (n; %) |
329 (41.4) |
154 (38.7) |
175 (44.1) |
|
Males (n; %) |
370 (46.5) |
194 (48.7) |
176 (44.3) |
|
Mean body mass index (kg/m2; SD) |
27.1 (4.5) |
27.0 (4.5) |
27.2 (4.5) |
|
Past or current significant medical history (n; %) |
715 (89.9) |
358 (89.9) |
357 (89.9) |
|
- risk factor a (n; %) |
419 (52.7) |
216 (54.3) |
203 (51.1) |
|
- history of allergy b (n; %) |
67 (8.4) |
29 (7.3) |
38 (9.6) |
|
Last influenza vaccination c |
|||
|
- previous season 2006-2007 (n; %) |
576 (72.5) |
287 (72.1) |
289 (72.8) |
|
- prior to previous season (n; %) |
57 (7.2) |
26 (6.5) |
31 (7.8) |
|
|
|||
|
Percentages are based on the number of randomised subjects having available data a At least one of the following: lung disease, heart disease, diabetes, renal disease, neurological abnormality or other significant medical history such as HIV, cancer, hepatitis (A, B, C), epilepsy, auto-immune diseases or blood disorders reported during the medical history review b At least one allergic condition reported as medical history c Percentages are calculated based on the number of randomised subjects who had previously been vaccinated against influenza and who had available data. 7 subjects (4 from the intradermal vaccine group and 3 from the adjuvanted vaccine group) had previously been vaccinated against influenza by the intradermal route |
|||
|
Van Damme et al. BMC Infectious Diseases 2010 10:134 doi:10.1186/1471-2334-10-134 |
|||
